Coya Therapeutics Q1 net loss $7.3M; pipeline milestones for COYA 302 detailed

Coya Therapeutics, Inc.

2025-Q1 EPS reported -$0.44 revenue$257,884

Net loss of $7.3M in Q1 2025 vs $5.1M in Q1 2024; R&D expense rose to $5.2M from $3.1M.
Cash and cash equivalents $35.5M as of March 31, 2025.
Positive interim results from investigator-initiated trial of LD IL-2 + CTLA4-Ig in Frontotemporal Dementia.
Expects IND submission for COYA 302 in ALS in Q2 2025; $8.4M milestone from DRL due upon first dosing.
Plans to file IND for COYA 302 in FTD by end of 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.